388 related articles for article (PubMed ID: 29957060)
1. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
2. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
3. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
5. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Shigeta K; Ishii Y; Hasegawa H; Okabayashi K; Kitagawa Y
World J Surg; 2014 Dec; 38(12):3248-56. PubMed ID: 25167895
[TBL] [Abstract][Full Text] [Related]
7. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
8. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.
Song K; Zhao W; Wang W; Zhang N; Wang K; Chang Z
Cancer Sci; 2018 Jun; 109(6):1939-1948. PubMed ID: 29700901
[TBL] [Abstract][Full Text] [Related]
9. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
[TBL] [Abstract][Full Text] [Related]
11. A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.
Zhao W; Chen B; Guo X; Wang R; Chang Z; Dong Y; Song K; Wang W; Qi L; Gu Y; Wang C; Yang D; Guo Z
Oncotarget; 2016 Apr; 7(14):19060-71. PubMed ID: 26967049
[TBL] [Abstract][Full Text] [Related]
12. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
13.
Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
[TBL] [Abstract][Full Text] [Related]
14. Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy.
Odin E; Sondén A; Gustavsson B; Carlsson G; Wettergren Y
Mol Med; 2015 Jul; 21(1):597-604. PubMed ID: 26193446
[TBL] [Abstract][Full Text] [Related]
15. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
16. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
20. HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Nakamura J; Kitajima Y; Kai K; Hashiguchi K; Hiraki M; Noshiro H; Miyazaki K
Int J Cancer; 2010 Sep; 127(5):1158-71. PubMed ID: 20020496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
